CONTROLLING INFLAMMATION

Investor and Analyst Call
November 7, 2019

- SHINE Study Open Label Extension Snapshot Results
- Strategy Update
Important Notice and Disclaimer

THIS PRESENTATION HAS BEEN PREPARED BY INFLARX N.V. (“INFLARX”), A US-NASDAQ PUBLICLY LISTED DUTCH COMPANY HAVING ITS PRINCIPLE PLACE OF BUSINESS IN GERMANY. THIS PRESENTATION IS MADE FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES. THE INFORMATION SET FORTH HEREIN DOES NOT PURPORT TO BE COMPLETE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THE DELIVERY OF THIS PRESENTATION AT ANY TIME, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF.

THIS PRESENTATION MAY CONTAIN FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE NEITHER HISTORICAL FACTS NOR ASSURANCES OF FUTURE PERFORMANCE. INSTEAD, THEY ARE BASED ON OUR CURRENT BELIEFS, EXPECTATIONS AND ASSUMPTIONS REGARDING THE FUTURE OF OUR BUSINESS, FUTURE PLANS AND STRATEGIES, OUR CLINICAL RESULTS AND OTHER FUTURE CONDITIONS. ALL STATEMENTS OTHER THAN STATEMENTS OF HISTORICAL FACTS CONTAINED IN THIS PRESENTATION, INCLUDING STATEMENTS REGARDING FUTURE RESULTS OF OPERATIONS AND FINANCIAL POSITION, BUSINESS STRATEGY, CURRENT AND PROSPECTIVE PRODUCT CANDIDATES, PLANNED CLINICAL TRIALS AND PRECLINICAL ACTIVITIES, PRODUCT APPROVALS, RESEARCH AND DEVELOPMENT COSTS, CURRENT AND PROSPECTIVE COLLABORATIONS, TIMING AND LIKELIHOOD OF SUCCESS, EXPECTATIONS REGARDING MARKET ACCEPTANCE AND SIZE, PLANS AND OBJECTIVES OF MANAGEMENT FOR FUTURE OPERATIONS, AND FUTURE RESULTS OF ANTICIPATED PRODUCT CANDIDATES, ARE FORWARD-LOOKING STATEMENTS. THESE RISKS AND UNCERTAINTIES INCLUDE THOSE DESCRIBED UNDER THE CAPTION “RISK FACTORS” IN INFLARX’S REGISTRATION STATEMENT ON FORM F-1 AND THE ACCOMPANYING PROSPECTUS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IN CONNECTION WITH THE COMPANY’S INITIAL PUBLIC OFFERING AND OTHER FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. NEW RISKS AND UNCERTAINTIES MAY EMERGE FROM TIME TO TIME, AND IT IS NOT POSSIBLE TO PREDICT ALL RISKS AND UNCERTAINTIES. EXCEPT AS REQUIRED BY APPLICABLE LAW, WE DO NOT PLAN TO PUBLICLY UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENTS CONTAINED HEREIN, WHETHER AS A RESULT OF ANY NEW INFORMATION, FUTURE EVENTS, CHANGED CIRCUMSTANCES OR OTHERWISE. ALTHOUGH WE BELIEVE THE EXPECTATIONS REFLECTED IN SUCH FORWARD-LOOKING STATEMENTS ARE REASONABLE, WE CAN GIVE NO ASSURANCE THAT SUCH EXPECTATIONS WILL PROVE TO BE CORRECT. ACCORDINGLY, READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS. NO REPRESENTATIONS OR WARRANTIES (EXPRESSED OR IMPLIED) ARE MADE ABOUT THE ACCURACY OF ANY SUCH FORWARD-LOOKING STATEMENTS.

CERTAIN INFORMATION CONTAINED IN THIS PRESENTATION RELATES TO OR IS BASED ON STUDIES, PUBLICATIONS, SURVEYS AND OTHER DATA OBTAINED FROM THIRD-PARTY SOURCES AND INFLARX’S OWN INTERNAL ESTIMATES AND RESEARCH. WHILE INFLARX BELIEVES THESE THIRD-PARTY SOURCES TO BE RELIABLE AS OF THE DATE OF THIS PRESENTATION, IT HAS NOT INDEPENDENTLY VERIFIED, AND MAKES NO REPRESENTATION AS TO THE ADEQUACY, FAIRNESS, ACCURACY OR COMPLETENESS OF, ANY INFORMATION OBTAINED FROM THIRD-PARTY SOURCES. IN ADDITION, ALL OF THE MARKET DATA INCLUDED IN THIS PRESENTATION INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND THERE CAN BE NO GUARANTEE AS TO THE ACCURACY OR RELIABILITY OF SUCH ASSUMPTIONS. FINALLY, WHILE WE BELIEVE OUR OWN INTERNAL RESEARCH IS RELIABLE, SUCH RESEARCH HAS NOT BEEN VERIFIED BY ANY INDEPENDENT SOURCE.
SHINE Study Open Label Extension Snapshot Results
**SHINE Study Patient Disposition for Open Label Extension (OLE)**

**SNAPSHOT ANALYSIS END OF SEP. 2019**
- End of Treatment (EOT) - week 40: Sept. 6th 2019 (completed at snapshot: n = 116)
- Last patient last visit (week 44): Oct. 4th 2019
- Final Data will be available early 2020

![Diagram]

**MAIN PERIOD**
- week 16
- OLE Period
  - week 40 + 4

**Patients Enrolled**
- n = 179

**Patients Dosed**
- n = 177 (100%)

**Entered Extension**
- n = 156 (88%)

**Completed OLE**
- n = 122 (69%)
  - visit at EOT at wk 40: n = 116
  - completed wk 44: n = 122

**Discontinued**
- n = 34 (19%)
**SHINE Study Details**

**Main Period**
- Placebo
- IFX-1 minimal dose (400mg q4w)
- IFX-1 low dose (800mg q4w)
- IFX-1 medium dose (800mg q2w)
- IFX-1 high dose (1200mg q2w)

**Open Label Extension Period**
- Week 16 HiSCR Responders: IFX-1 low dose (800mg q4w)
- Week 16 HiSCR Non-Responders: IFX-1 medium dose (800mg q2w)

**Screening**
16 weeks (double blind)

**TOTAL TREATMENT TIME:** 9 months + 1 month observation

**OPEN LABEL EXTENSION PHASE KEY GOALS:**
- HiSCR responders: Determine if **maintain response** with **low dose IFX-1 therapy**
- HiSCR non-responders: Determine if **become responders** when **transitioned to medium dose IFX-1 therapy**

**Important Note:** Patients entering the OLE were not unblinded to their initial therapy
Comparison of HiSCR for Week 16 Responder versus Non-responder Groups (OLE) Over Time

Responders: 71% maintain HiSCR response with low dose IFX-1
Non-responders: 42% become HiSCR responders with medium dose IFX-1

* full analysis set
Inflammatory Lesion Reductions in all OLE Patients at End of Treatment (week 40) Compared to Placebo Group Performance in Main Period

Marked improvement of all inflammatory lesions over time – not explainable by placebo effect

Relative Reduction (% mean) of Counts / Scores compared to Respective Baseline (Day1)*

of all OLE patients on week 40 (n=116)

- AN count
- DF count
- IHS-4 score
- ANF count

OLE patients week 40

-66.9
-46.0
-54.5
-60.9

of Placebo patients on week 16

- AN count
- DF count
- IHS-4 score
- ANF count

placebo group week 16

-26.5
-17.7
-21.4
-26.3

* full analysis set (unadjusted)
AN Count Reduction of all Patients in OLE until End of Treatment

Continued improvement with reduction of AN count throughout treatment period

* full analysis set
IHS-4 Score: Includes and Weights All Inflammatory Lesions

<table>
<thead>
<tr>
<th>IHS-4 points = sum of</th>
<th>HS STAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>number of inflammatory nodules</td>
<td>x 1</td>
</tr>
<tr>
<td>number of abscesses</td>
<td>x 2</td>
</tr>
<tr>
<td>number of draining fistulas</td>
<td>x 4</td>
</tr>
</tbody>
</table>

- Developed by KOL´s / Physicians to establish a new severity scoring system, suitable for tracking treatment response
- Captures reduction of draining fistulas (unlike HiSCR)
- Weights the most fluctuating lesions (infl. nodules) less than abscesses or fistula – lower variability
- Internal validation work shows correlation with DLQI and Pain Scores in SHINE data set
IHS-4 Scores Over Time in OLE: Non-responders versus Responders

Change in **IHS-4 scores** between week 16 and week 40 in week 16 HiSCR **responders versus non-responders***

Non-Responders
(n = 84)

Responders
(n = 72)

- **800 mg IFX-1 q4w**
- **800 mg IFX-1 q2w**

* full analysis set

**Non-responders improve under medium dose IFX-1 treatment during OLE**

**Responders are relatively “stable” with their IHS-4 scores on low dose IFX-1**
IHS-4 Scores in OLE Patients: Relative Change from Baseline (Day 1) HiSCR Non-responder Group (week 16)

**IHS-4 scores**: Relative change from baseline in OLE patients at week 16 and week 40 in HiSCR non-responder patients (week 16) – displayed per Main Period Treatment group*

Main period placebo and minimal dose patients show strongest improvement in IHS-4 scores when being treated with medium IFX-1 dose (for week 16 HiSCR Non-Responders)

* Last observation carried forward analysis set
IHS-4 Scores in OLE Patients: Relative Change from Baseline (Day 1) HiSCR Responder Group (week 16)

**IHS-4 Scores** relative change to baseline in OLE patients at week 16 and week 40 in week 16 HiSCR responders - displayed per Main Period Treatment group*

**Main period HiSCR responders** maintain or slightly lose their IHS-4 score improvements when treated with the low dose IFX-1

* Last observation carried forward analysis set
SHINE Study – Insights into Pharmacokinetics/Pharmacodynamics

LEARNINGS FROM SHINE STUDY PK/PD AND RELATED MODELING

- Results indicate that IFX-1 consumption in HS is much higher than in other diseases (trough levels are a multiple lower at same dose)
- Results further indicate that this consumption in HS is likely driven by a very high C5a turnover rate
- Models suggest a target mediated drug clearance: this means, the higher the generation rate of C5a the higher the IFX-1 clearance
- Models suggest that IFX-1 achieves a good tissue penetration rate, especially for higher dose groups
Key Takeaways of SHINE Study OLE – EOT Snapshot Analysis

- Long-term treatment with IFX-1 leads to a marked improvement of inflammatory lesion counts in HS patients over time.

- HiSCR responders maintained response (>70%) over time even when treated with low dose IFX-1.

- Placebo and minimal dose group patients in the HiSCR Non-responder group demonstrated a marked improvement in inflammatory lesion counts when transitioned to IFX-1 800mg every other week.

- IFX-1 treatment was well tolerated, no drug related SAEs in OLE.
Q3 2019 Financials & Strategy Update
### Key financial figures Q1–Q3 2019 / 2018

<table>
<thead>
<tr>
<th>in € million</th>
<th>Q1-Q3 2019</th>
<th>Q1-Q3 2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P&amp;L</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>(33.6)</td>
<td>(16.0)</td>
<td>&gt;(100%)</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>(9.4)</td>
<td>(9.2)</td>
<td>(2.2%)</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>(43.0)</td>
<td>(25.2)</td>
<td>(70.6%)</td>
</tr>
<tr>
<td>Other income</td>
<td>0.1</td>
<td>0.2</td>
<td>(50.0%)</td>
</tr>
<tr>
<td>Net financial Result</td>
<td>3.3</td>
<td>5.4</td>
<td>(38.9%)</td>
</tr>
<tr>
<td><strong>Loss for the period</strong></td>
<td>(39.6)</td>
<td>(19.6)</td>
<td>&gt; (100%)</td>
</tr>
<tr>
<td><strong>EPS in € (basic and diluted)</strong></td>
<td>(1.53)</td>
<td>(0.79)</td>
<td>&gt; (100%)</td>
</tr>
</tbody>
</table>

| **Cash & marketable securities** | | | |
| Cash and cash equivalents at beginning of period | 55.4 | 123.3 | (55.1%) |
| Net cash from operating activities | (27.0) | (15.2) | (77.3%) |
| Net change in cash and cash equivalents | (28.4) | (67.0) | (57.6%) |
| Cash and cash equivalents at end of period | 27.0 | 56.3 | (52.0%) |
| Marketable securities | 108.5 | 105.8 | 2.6% |
| **Cash & marketable securities** | 135.5 | 162.1 | (16.4%) |

Rounding differences may occur
Strategy update

CONTINUE DEVELOPMENT OF ANTI-C5A TECHNOLOGY

• Develop IFX-1 in current and new indications
• Enlarge running trial in Pyoderma Gangraenousum
• Initiate clinical proof-of-concept trial in oncology in 2020
• With positive OLE results, evaluate options for further development in HS
  – discuss data and next steps with regulatory authorities

BROADEN R&D PIPELINE BEYOND ANTI-C5A TECHNOLOGY AS PART OF DIVERSIFICATION STRATEGY

• Focus on rare and inflammatory diseases with high unmet medical need and defined oncology space
• Experienced head of global business development and strategy with pharmaceutical background hired in the US to foster diversification strategy

Company has sufficient financial resources to carry out this strategy and reach key value inflection points
Thank you for your attention

InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Germany
Email: info@inflarx.com
Tel: +49-3641-508180
Fax: +49-3641-508181
www.inflarx.com